Pink Sheet reporter and editor discuss the implications of the FDA decision to cancel meetings and postpone inspections, as well as its new Type 2 Diabetes drug development guidance.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
This website doesn't track the visitors or use any cookies. Made by Alex Barredo. Send your feedback to alex@barredo.es.
